No quarterly revenue total was found in MEDICUS PHARMA LTD.'s SEC filings.
Medicus Pharma Ltd. (MDCX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $15.2 million in cash and investments and $137,330 in total debt.
Revenue
—
Net income
$-11.62M
-88.1% vs year-ago quarter
Operating cash flow
$-6.98M
-27.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.21
+51.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
63.18M
+254.6% vs year-ago quarter
Net cash
$15.04M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDCX (Nasdaq), MDCXW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- W. Conshohocken, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1997296
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$11.5M | -$8.6M | -$7.8M | -$15 | -$6.0M |
| Net income | -$11.6M | -$9.0M | -$15.1M | -$20.9M | -$6.2M |
| Diluted EPS | -$0.21 | -$0.31 | -$0.81 | -$1.12 | -$0.43 |
| Operating cash flow | -$7.0M | -$9.0M | -$6.6M | -$6.8M | -$5.5M |
| Total assets | $27.1M | $7.4M | $10.1M | $10.0M | $11.9M |
| Total liabilities | $28.8M | $6.0M | $10.0M | $10.8M | $8.7M |
| Stockholders' equity | -$1.8M | $1.3M | -$67,554 | -$910,126 | — |
| Cash and investments | $15.2M | $6.4M | $8.7M | $8.7M | $9.7M |
| Total debt | $137,330 | $174,394 | $205,595 | $236,258 | $266,155 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Oct 23, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 16, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Agreement ended
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 11, 2026 | Sep 4, 2026 |
All 343 Medicus Pharma Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.